BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19446406)

  • 1. Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study.
    Ahmed A; Powers MP; Youker KA; Rice L; Ewton A; Dunphy CH; Chang CC
    Pathol Res Pract; 2009; 205(9):634-8. PubMed ID: 19446406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
    Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
    Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms.
    Keski H
    Blood Cells Mol Dis; 2020 May; 82():102420. PubMed ID: 32179412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression.
    Panteli K; Zagorianakou N; Bai M; Katsaraki A; Agnantis NJ; Bourantas K
    Eur J Haematol; 2004 Jun; 72(6):410-5. PubMed ID: 15128419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.
    Tadmor T; Bejar J; Attias D; Mischenko E; Sabo E; Neufeld G; Vadasz Z
    Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrosis in Hodgkin and non-Hodgkin lymphomas.
    Tataroglu C; Sarioglu S; Kargi A; Ozkal S; Aydin O
    Pathol Res Pract; 2007; 203(10):725-30. PubMed ID: 17804176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
    Tefferi A; Thiele J; Vardiman JW
    Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
    Santana-Davila R; Tefferi A; Holtan SG; Ketterling RP; Dewald GW; Knudson RA; Steensma DP; Chen D; Hoyer JD; Hanson CA
    Leuk Res; 2008 Dec; 32(12):1927-30. PubMed ID: 18538839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of significance of bone marrow microvessel density in myeloproliferative neoplasms in correlation with CD34 blasts, mast cell count and fibrosis.
    Thomas K; Rao R; G V C; Rai S; Rao A R S; Basavaraju Vatsala K
    F1000Res; 2023; 12():503. PubMed ID: 38434629
    [No Abstract]   [Full Text] [Related]  

  • 12. [Histopathology and molecular pathology of chronic myeloproliferative disorders].
    Kreipe HH
    Veroff Pathol; 1993; 141():1-158. PubMed ID: 8372486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
    Medinger M; Tzankov A; Kern J; Pircher A; Hermann M; Ott HW; Gastl G; Untergasser G; Gunsilius E
    Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloproliferative diseases on a pathologist's desk--a dilemma of distinct entities versus a clinico-pathologic continuum. A descriptive study based on a material from the Polish population.
    Rudzki Z; Papla B; Stachura J
    Pol J Pathol; 2004; 55(1):13-23. PubMed ID: 15195702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease.
    Stevens EC; Rosenthal NS
    Am J Clin Pathol; 2001 Aug; 116(2):177-82. PubMed ID: 11488063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pathology of myeloproliferative neoplasms.
    Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
    Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The value of the initial bone biopsy in chronic myeloproliferative syndromes. Review of 80 cases].
    Ortuño F; Zuazu I; Bordes R; Brunet S; Puig J; Ayats R
    Sangre (Barc); 1989 Apr; 34(2):117-25. PubMed ID: 2667169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis.
    Hahn HP; Hornick JL
    Am J Surg Pathol; 2007 Nov; 31(11):1669-76. PubMed ID: 18059223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies.
    Ellis JT; Peterson P; Geller SA; Rappaport H
    Semin Hematol; 1986 Apr; 23(2):144-55. PubMed ID: 3704666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bone marrow in urticaria pigmentosa and systemic mastocytosis. Cell composition and mast cell density in relation to urinary excretion of tele-methylimidazoleacetic acid.
    Ridell B; Olafsson JH; Roupe G; Swolin B; Granerus G; Rödjer S; Enerbäck L
    Arch Dermatol; 1986 Apr; 122(4):422-7. PubMed ID: 3954410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.